PharmaCyte Biotech, Inc.

PharmaCyte Biotech (PMCB) shows no detected cyber incidents or red-flag 8-K filings in our 90-day monitoring window. However, absence of recent signal doesn't indicate absence of risk—biotech companies face sustained dilution pressures and financing volatility that require deeper historical context. The full $49 Report extends analysis to 12 months of filing history, calculates dilution risk scores, maps financing patterns, and surfaces AI-detected risk signals across SEC documents. The full $49 Report adds quantified dilution trajectory, 12-month red-flag context, and financing-linked volatility assessment.